> Real-time Quotes & News

Real-time Quotes

Product
Bid
Ask
High
Low
Previous Close
*The above quotes are for reference only

Real-time News

2025-11-04

The European Commission: We will continue to work to restore the normal functioning of supply chains while safeguarding the EU's economic security.

The European Commission: We will continue to work to restore the normal functioning of supply chains while safeguarding the EU's economic security.
2025-11-04

US biotechnology company Metsera: The revised Pfizer (PFE.N) proposal requires partner companies to issue a statement indicating that "the Novo Nordisk (NVO.N) proposal is too risky and not feasible".

US biotechnology company Metsera: The revised Pfizer (PFE.N) proposal requires partner companies to issue a statement indicating that "the Novo Nordisk (NVO.N) proposal is too risky and not feasible".
2025-11-04

US biotechnology company Metsera: The merger agreement with Pfizer (PFE.N) remains in effect. Under the Pfizer merger agreement, Metsera and Pfizer can negotiate potential adjustments within two business days.

US biotechnology company Metsera: The merger agreement with Pfizer (PFE.N) remains in effect. Under the Pfizer merger agreement, Metsera and Pfizer can negotiate potential adjustments within two business days.
2025-11-04

US biotechnology company Metsera: Novo Nordisk (NVO.N)'s offer is better than Pfizer's (PFE.N) revised proposal, which values the company at up to $70 per share, totaling approximately $8.1 billion.

US biotechnology company Metsera: Novo Nordisk (NVO.N)'s offer is better than Pfizer's (PFE.N) revised proposal, which values the company at up to $70 per share, totaling approximately $8.1 billion.
2025-11-04

Novo Nordisk (NVO.N) has proposed valuing the U.S. biotechnology company Metsera at $86.20 per share, totaling $10 billion.

Novo Nordisk (NVO.N) has proposed valuing the U.S. biotechnology company Metsera at $86.20 per share, totaling $10 billion.
2025-11-04

U.S. biopharmaceutical company Metsera and Pfizer (PFE.N) may hold two days of talks regarding potential adjustments.

U.S. biopharmaceutical company Metsera and Pfizer (PFE.N) may hold two days of talks regarding potential adjustments.
Previous 1 ... 16 17 18 19 20 ... 117 Next